تقرير
Split-scalp pilot study to evaluate effectiveness of Minoxidil 0,5% MMP® versus Topical Minoxidil 5% in the treatment of Female Pattern Hair Loss.
| العنوان: | Split-scalp pilot study to evaluate effectiveness of Minoxidil 0,5% MMP® versus Topical Minoxidil 5% in the treatment of Female Pattern Hair Loss. |
|---|---|
| المؤلفون: | Corrêa, Adriana C, Machado, Carla J, Carneiro, Sueli C S |
| المصدر: | Arch Dermatol Res ; ISSN:1432-069X ; Volume:316 ; Issue:6 |
| بيانات النشر: | Springer |
| سنة النشر: | 2024 |
| المجموعة: | PubMed Central (PMC) |
| مصطلحات موضوعية: | Androgenetic alopecia, Female Pattern Hair Loss, Medicine microinfusion into the skin (MMP®), Minoxidil, Scalp microinfusion, Transdermal drug delivery |
| الوصف: | Female Pattern Hair Loss (FPHL) is a common form of non-scaring hair loss that occurs in adult women. Although several treatments have already been proposed for FPHL, only Topical Minoxidil accumulated an adequate level of evidence. This study aimed to evaluate the therapeutic response of MMP® (intradermal infiltration) of Minoxidil formulation in the frontal-parietal-vertex regions compared with the gold-standard home administration of Minoxidil 5% Capillary Solution. This self-controlled comparative study evaluated 16 FPHL patients, without treatment for at least 6 months, confirmed by trichoscopy with TrichoLAB® software. They received 4 monthly sessions of MMP® with Minoxidil 0,5% on the right side of the scalp (frontal-parietal-vertex areas), followed by occlusion with plastic film for 12 h and prescription of Minoxidil 5% Solution for home use once a day, on both scalp sides, starting 72 h after the procedure. The reassessment trichoscopy was 6 weeks after the last session and they answered a "self-assessment" questionnaire. Treated scalp areas were compared and showed both treatments, in general, were effective, with no difference between them. If they were analyzed separately by treated areas, there were signs of better response in the parietal-vertex regions with treatment by MMP® with Minoxidil, while clinical treatment indicated a better response in the other regions. When patients were divided into more and less advanced cases, a better response in parietal-vertex regions treated by MMP® with Minoxidil in less advanced patients was confirmed. MMP® with Minoxidil showed a better response in the parietal-vertex regions in less advanced FPHL patients. It represents yet another resource to improve quality of life of these suffering patients. |
| نوع الوثيقة: | report article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1007/s00403-024-03053-6Test; https://pubmed.ncbi.nlm.nih.gov/38822940Test |
| DOI: | 10.1007/s00403-024-03053-6 |
| الإتاحة: | https://doi.org/10.1007/s00403-024-03053-6Test https://pubmed.ncbi.nlm.nih.gov/38822940Test |
| حقوق: | © 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
| رقم الانضمام: | edsbas.AB56C38D |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s00403-024-03053-6 |
|---|